Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME

被引：0
作者：
Jurisic-Erzen, D. [1 ]
Johansen, O. [2 ]
George, J. [3 ]
Mattheus, M. [3 ]
Zinman, B. [4 ,5 ]
Inzucchi, S. [6 ]
机构：
[1] Univ Hosp Ctr Rijeka, Rijeka, Croatia
[2] Boehringer Ingelheim Norway KS, Asker, Norway
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
732
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [41] Empagliflozin and Progression of Kidney Disease in Patients at High Renal Risk: Slope Analyses from EMPA-REG OUTCOME®
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    Von Eynatten, Maximilian
    Groop, Per-Henrik
    DIABETES, 2017, 66 : A314 - A314
  • [42] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Lund, S. S.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1091 - 1091
  • [43] Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
    Coleman, R. L.
    Gray, A.
    Broedl, U. C.
    Fitchett, D.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    Holman, R. R.
    DIABETIC MEDICINE, 2017, 34 : 23 - 23
  • [44] Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Khunti, Kamlesh
    Fitchett, David H.
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Ofstad, Anne Pernille
    Zinman, Bernard
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09) : 3025 - 3035
  • [45] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
    Odutayo, Ayodele
    Zinman, Bernard
    Wanner, Christoph
    Zwiener, Isabella
    Lund, Soren S.
    Hantel, Stefan
    Fitchett, David
    Udell, Jacob A.
    CJC OPEN, 2024, 6 (07) : 868 - 875
  • [46] Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial
    Pellicori, P.
    Ofstad, A. Pernille
    Fitchett, D.
    Zeller, C.
    Wanner, C.
    George, J.
    Zinman, B.
    Brueckmann, M.
    Lindenfeld, J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1586 - 1586
  • [47] Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
    Coleman, R. L.
    Gray, A. M.
    Broedl, U. C.
    Fitchett, D.
    George, J. T.
    Woerle, H. -J.
    Zinman, B.
    Holman, R. R.
    DIABETOLOGIA, 2017, 60 : S522 - S522
  • [48] ARE THE CARDIOVASCULAR RISK REDUCTIONS SEEN WITH EMPAGLIFLOZIN IN THE EMPA-REG OUTCOME TRIAL EXPLAINED BY CONVENTIONAL CARDIOVASCULAR RISK FACTORS?
    Fitchett, David H.
    Coleman, Ruth L.
    Gray, Alistair
    Broedl, Uli C.
    George, Jyothis
    Woerle, Hans-Juergen
    Zinman, Bernard
    Holman, Rury R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1809 - 1809
  • [49] Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME
    Schnee, J.
    Inzucchi, S. E.
    Zinman, B.
    McGinniss, J.
    George, J. T.
    Fitchett, D.
    DIABETOLOGIA, 2017, 60 : S85 - S86
  • [50] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
12345